Is BPH cancer?
No, BPH is Benign Prostatic Hyperplasia, a benign condition and unrelated to prostate cancer; however, it can greatly affect a man’s quality of life. BPH is NOT a type of cancer.
What happens when BPH is left untreated? Are there any long-term risks?
If left untreated, BPH can lead to permanent bladder damage.1 When the bladder does not empty completely, the risk of developing urinary tract infections (UTIs) may increase.2 Other serious problems can also develop over time, including bladder stones, blood in the urine, incontinence, or urinary retention.2
When should I seek BPH treatment?
You may want to seek BPH treatment if you experience BPH symptoms such as urgent need to urinate, difficulty starting your urine stream, need to push or strain when urinating, dribbling, the sensation that the bladder is not empty after urinating, weak urine flow, increased frequency of urination, frequent nighttime urination, burning or pain during urination.3
What happens post-treatment, during the recovery period? Are meds required?
After the treatment, patients typically go home the same day without a catheter. There is minimal downtime post-treatment and many patients experience symptom relief in as early as 2 weeks.4 Patients may experience some urinary discomfort during the recovery period. The most common side effects may include blood in the urine, some pain or discomfort when urinating, some increased urge to go and discomfort in the pelvis that typically resolve within two to four weeks after the procedure.4
What happens if implants need to be removed?
The implant is made up of standard surgical implantable materials: a nitinol tab, a stainless-steel tab, and polyester suture that holds the two tabs together. Your doctor can remove the implant from the urethra, if needed.
Does the treatment affect my sexual function?
Clinical studies have shown the UroLift System treatment does not cause new, sustained instances of sexual dysfunction.4 The same cannot always be said of other BPH therapies such as TURP, laser, and even medication.
Will the UroLift Implans affect a digital rectal exam (DRE)?
The implants are not expected to interfere with a DRE. The implants are placed on the anterior (front) side of the prostate, and a DRE is conducted on the posterior (back) side of the prostate.
How does the UroLift System treatment compare with other treatment options?
The UroLift® System treatment has been found to be a safe and effective treatment for symptoms related to BPH. Its risk profile is better than most traditional surgical options, and patients report symptom relief better than reported with medications.5,6 In clinical studies, there have been no instances of new, sustained erectile dysfunction or ejaculatory dysfunction.4
What clinical data is available?
We have over 25 peer-reviewed publications demonstrating the UroLift System is safe and effective. Improvement in urinary symptoms, as seen through reduction in IPSS (International Prostate Symptom Score), has been consistent across the various studies, showing rapid relief in as early as two weeks and sustained effect to five years.5
What are the side effects?
In our clinical studies, the most common side effects reported were mild to moderate and include pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate and/or the inability to control the urge. Most symptoms resolved within two to four weeks after the procedure.4
Does my insurance cover the treatment?
The UroLift System treatment is covered by Medicare and many private insurers. Contact your insurance provider for your specific coverage information.
1. Tubaro et al. 2003 Drugs Aging 2. Lieber et al. Prostate volume and prostate-specific antigen in the absence of prostate cancer: a review of the relationship and prediction of long-term outcomes, Prostate 2001 3. Barry M, Roehrborn C. Management of benign prostatic hyperplasia. Annu Rev Med.1997 4. Abrams, et al., Neurourology and Urodynamics 2002; Maximilian, et al., BJU Intl 2012 5. Roehrborn et al. Journal of Urology 2013 LIFT Study 6. Sonksen, EU Urol, 2015 BPH6 Study 7. Roehrborn et al. Can J Urol 2017